Quick Takeaways
- This page summarizes Everett Rand Sutherland's Form 4 filing for Krystal Biotech, Inc. (KRYS).
- 1 reported transaction and 1 derivative row are listed below.
- Filing timestamp: 31 Jan 2022, 15:47.
Everett Rand Sutherland - 31 Jan 2022 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)
- Role
- Director
- Signature
- Krish Krishnan, as Attorney-in-Fact
- Issuer symbol
- KRYS
- Transactions as of
- 31 Jan 2022
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 31 Jan 2022, 15:47:06 UTC
- Previous filing
- 26 Jan 2022
- Next filing
- 01 Jul 2022
- SEC
- View on sec.gov
Quoteable Key Fact
"Everett Rand Sutherland filed Form 4 for Krystal Biotech, Inc. (KRYS) on 31 Jan 2022."
What Changed
- Previous filing in this sequence was filed on 26 Jan 2022.
- Current net transaction value: $0.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Source Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
KRYS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +13,600
- Change %
- Price
- $0.000000
- Shares after
- 13,600
- Date
- 31 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 13,600
- Exercise price
- $59.00
- Footnotes
- F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | The options were awarded on January 31, 2022 and vest in equal monthly tranches over a three-year period. |